Disease clearance – a new horizon in ulcerative colitis

Česká verze

Authors: I. Šturdík; A. Gojdičová; S. Majna; J. Skubáková; Z. Vrablicová; J. Tóth; T. Hlavatý
Authors place of work: Gastroenterologické centrum Bezručova, Poliklinika Bezručova, Bratislava
Published in the journal: Gastroent Hepatol 2025; 79(5): 390-395
Category: Přehledová práce
doi: https://doi.org/10.48095/ccgh2025390

Summary

Therapeutic targets in ulcerative colitis have evolved from symptomatic control to a treat-to-target strategy, where endoscopic remission has become a key objective. However, persistent histological activity in patients in endoscopic remission poses a risk of relapse, which has led to the proposal of a new, more ambitious goal –⁠ “disease clearance.” This concept represents a composite endpoint comprising of simultaneous achievement of clinical, endoscopic, and histological remission. Growing evidence confirms that achieving “disease clearance” is associated with significantly better long-term outcomes, including a lower risk of hospitalizations and surgery. Furthermore, landmark results from the VERDICT trial have shown that with a treat-to-target strategy using vedolizumab, this stringent target is achievable in up to 67.2% of patients at 48 weeks, particularly when treatment is initiated early. Thus, “disease clearance” represents a new horizon in the management of ulcerative colitis with the potential to alter the natural course of the disease. Although its implementation poses challenges, it shifts the treatment paradigm towards the complete suppression of inflammatory activity and personalized medicine.

Keywords:

ulcerative colitis – disease clearance – treat-to-target – vedolizumab – histological remission

Zdroje

1. Jairath, V, Zou G, Wang Z et al. Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim

analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol 2024; 11 (1): e001218. doi: 10.1136/bmjgast-2023 -⁠ 001218.

2. Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160 (5): 1570–1583. doi: 10.1053/ j.gastro.2020.12.031.

3. Schreiber S, Danese S, Dignass A et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: International Delphi Consensus Recommendations. J Crohns Colitis 2024; 18 (1): 91–105. doi: 10.1093/ecco-jcc/jjad130.

4. D’Amico F, Magro F, Siegmund B et al. Disease clearance as a new outcome in ulcerative colitis: a systematic review and expert consensus. Inflamm Bowel Dis 2024; 30 (6): 1009–1017. doi: 10.1093/ibd/izad159.

5. D’Amico F, Fiorino G, Solitano V et al. Ulcerative colitis: impact of early disease clearance on long-term outcomes –⁠ a multicenter cohort study. United European Gastroenterol J 2022; 10 (7): 775–782. doi: 10.1002/ueg2.12288.

6. Danese S, Schreiber S, Loftus E et al. P271 Evolving targets in ulcerative colitis: defining disease clearance in the VARSITY study. J Crohns Colitis 2021; 15 (Suppl 1): S305. doi: 10.1093/ecco-jcc/jjab076.396.

7. Sands BE, Peyrin-Biroulet L, Loftus ED et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381 (13): 1215–1226. doi: 10.1056/NEJMoa 1905725.

8. Nascimento C, Revés J, Ramos LR et al. P406 disease clearance in patients with ulcerative colitis treated with aminosalicylates. J Crohns Colitis 2022; 16 (Suppl 1): i398. doi: 10.1093/ ecco-jcc/jjab232.533.

9. Danese S et al. P0417 effects of ustekinumab induction and maintenance therapy on disease clearance in the unifi phase 3 study in ulcerative colitis. United European Gastroenterol J 2021; 9 (S8): 262–907. doi: 10.1002/ueg2.12144.

10. Jairath V, Zou GY, Adsul S et al. DOP050 target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial. Gastroenterology 2025; 169 (Suppl 1): S268. doi: 10.1016/S0016-5085 (25) 01562-8.

11. Jairath V, Peyrin-Biroulet L, Magro F et al. DOP007 change in histological inflammation in patients with ulcerative colitis treated with vedolizumab: results from the continuing VERDICT trial. J Crohns Colitis 2025; 19 (Suppl 1): i92–i93. doi: 10.1093/ecco-jcc/jjae190.0046.

ORCID autorov

A. Gojdičová 0000-0003-1124-4628,

S. Majna 0009-0007-9832-436X,

T. Hlavatý 0000-0003-2555-9081.

Doručené/Submitted: 13. 8. 2025

Prijaté/Accepted: 25. 8. 2025

Korespondenčný autor

MUDr. Igor Šturdík, PhD.

Gastroenterologické centrum Bezručova

Poliklinika Bezručova

Bezručova 2531/5

811 09 Bratislava